Literature DB >> 2164835

Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

P Price1, H D Sinnett, B Gusterson, G Walsh, R P A'Hern, J A McKinna.   

Abstract

Between 1972 and 1982, 60 patients with histologically proven duct carcinoma in situ (DCIS) without evidence of invasive disease were treated by surgery alone. Treatment was not randomised and was total mastectomy (19), subcutaneous mastectomy (6) or local excision (35). Follow-up was by clinical examination and mammography with a median follow-up of 9 years (range 4-16 years). Twenty-six patients (43%) have recurred locally. The estimated proportion recurrence free at 7 years is 59% (95% CI 46-72%). Local recurrence on the chest wall occurred in one patient having total mastectomy and in the chest wall or nipple in three patients having subcutaneous mastectomy. Twenty-two patients recurred locally in the breast after conservative surgery. The 7-year recurrence-free rates were 94%, 44% and 45% respectively in the three groups. Of those patients who recurred locally 14/26 (54%) did so with invasive disease. Of the 34 who did not develop local recurrence, two developed metastases. The only factor which correlated with local recurrence and invasive local recurrence on multivariate analysis was conservative surgery (hazard ratio 4.71 (1.59-14.0), P = 0.001, and 4.05 (1.00-18.7), P = 0.03, respectively). DCIS can be an aggressive local disease and local excision may be inadequate treatment.

Entities:  

Mesh:

Year:  1990        PMID: 2164835      PMCID: PMC1971672          DOI: 10.1038/bjc.1990.194

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Intraductal carcinoma of the breast. A comparative study.

Authors:  K C Westbrook; H S Gallager
Journal:  Am J Surg       Date:  1975-12       Impact factor: 2.565

2.  Multicentricity of breast carcinoma demonstrated by routine correlated serial subgross and radiographic examination.

Authors:  M D Lagios
Journal:  Cancer       Date:  1977-10       Impact factor: 6.860

3.  Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment.

Authors:  P P Rosen; R Senie; D Schottenfeld; R Ashikari
Journal:  Ann Surg       Date:  1979-03       Impact factor: 12.969

4.  Current concepts in the detection and treatment of the earliest of the early breast cancers.

Authors:  J H Farrow
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

5.  Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; P Price; A McKinna; S Harrison
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

6.  Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). I. Observations concerning the multicentricity of mammary cancer.

Authors:  E R Fisher; R Gregorio; C Redmond; F Vellios; S C Sommers; B Fisher
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

7.  Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures.

Authors:  M D Lagios; P R Westdahl; F R Margolin; M R Rose
Journal:  Cancer       Date:  1982-10-01       Impact factor: 6.860

8.  Multicentricity of non-palpable breast cancer.

Authors:  G F Schwartz; A S Patchesfsky; S A Feig; G S Shaber; A B Schwartz
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

9.  Intraductal "noninfiltrating" carcinoma of the breast.

Authors:  P W Brown; J Silverman; E Owens; D C Tabor; J J Terz; W Lawrence
Journal:  Arch Surg       Date:  1976-10

10.  Prospective study of non-infiltrating carcinoma of the breast.

Authors:  R Ashikari; A G Huvos; R E Snyder
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

View more
  9 in total

1.  A Case of Ductal Carcinoma In Situ (DCIS:noncomedo type)Detected by Ultrasonography: Demonstration of Occult Multiple Foci.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

Review 2.  Management of ductal carcinoma in situ of the breast.

Authors:  N J Carty; C Carter; G T Royle; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1995-05       Impact factor: 1.891

3.  Ductal carcinoma in situ detected by screening.

Authors: 
Journal:  BMJ       Date:  1990-09-01

Review 4.  Familial breast cancer.

Authors:  D G Evans; I S Fentiman; K McPherson; D Asbury; B A Ponder; A Howell
Journal:  BMJ       Date:  1994-01-15

5.  Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.

Authors:  Nils D Arvold; Rinaa S Punglia; Melissa E Hughes; Wei Jiang; Stephen B Edge; Sara H Javid; Christine Laronga; Joyce C Niland; Richard L Theriault; Jane C Weeks; Yu-Ning Wong; Sandra J Lee; Michael J Hassett
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

Review 6.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

7.  Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Authors:  Michael J Hassett; Wei Jiang; Laurel A Habel; Larissa Nekhlyudov; Ninah Achacoso; Luana Acton; Stuart J Schnitt; Deb Schrag; Rinaa S Punglia
Journal:  Breast Cancer Res Treat       Date:  2016-02-03       Impact factor: 4.872

8.  The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ.

Authors:  P A Holland; A Gandhi; W F Knox; M Wilson; A D Baildam; N J Bundred
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

9.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

Authors:  F Wärnberg; H Nordgren; L Bergkvist; L Holmberg
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.